This week's FierceBiotech is brought to you by Clinipace.


Endpoints in Heart Failure Clinical Trials: Challenges and Potential Resolutions

Register for the FREE webcast now

Presentation on Thursday, July 28th, 2016 @ 11:30am ET

While primary treatment objectives for chronic heart failure, the fourth leading cause of adult hospitalizations in the US, are to improve quality of life and increase survival, we have not determined the best measures to assess whether we have achieved those objectives in clinical trials or practice.

The selection of primary endpoints for heart failure clinical trials is quite challenging, with important implications for patients, the medical community and regulatory agencies. The endpoints must be easy to diagnose, free of measurement errors, directly linked to property of interest and have the ability to generalize to a wider population.

Tune in to this FREE webcast to better understand:

  • Heart failure endpoint characteristics
  • Objectives and endpoints by phase
  • Surrogate endpoints in heart failure trials
  • and much more

Interested but can't attend the live presentation? Register anyway and we'll send you a link to the recording and slides.

Register for the webcast now

North America | Latin America | Europe | Asia Pacific



Want to reach 160,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.



About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe.

FierceMarkets 1900 L St. NW Suite we 400  Washington, DC 20036

.